← All trials
NCT06052696
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2023
- Primary completion
- Dec 1, 2028
- Completion date
- Dec 1, 2030
- First posted
- Sep 25, 2023
- Last posted
- Sep 25, 2023
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Erasmus University RotterdamLead sponsor
- Erasmus University RotterdamReponsible party - principal investigator
- Dutch Cancer SocietyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.